Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe
Portfolio Pulse from
Eli Lilly's drug Jaypirca has received a positive opinion from the CHMP for use in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) in a post-BTK inhibitor setting.
March 03, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Jaypirca has received a positive opinion from the CHMP for treating relapsed or refractory CLL in Europe, potentially expanding its market and boosting sales.
The CHMP's positive opinion is a significant step towards approval in Europe, which could lead to increased sales and market presence for Eli Lilly's Jaypirca. This development is likely to positively impact LLY's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90